nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—CYP2C9—Capecitabine—esophageal cancer	0.0494	0.665	CbGbCtD
Bicalutamide—CYP2C9—Cisplatin—esophageal cancer	0.0249	0.335	CbGbCtD
Bicalutamide—Enzalutamide—ABCB1—esophageal cancer	0.0052	1	CrCbGaD
Bicalutamide—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00293	0.00547	CcSEcCtD
Bicalutamide—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.00291	0.00545	CcSEcCtD
Bicalutamide—Injection site reaction—Capecitabine—esophageal cancer	0.0029	0.00541	CcSEcCtD
Bicalutamide—Herpes zoster—Methotrexate—esophageal cancer	0.00288	0.00538	CcSEcCtD
Bicalutamide—Melaena—Capecitabine—esophageal cancer	0.00285	0.00532	CcSEcCtD
Bicalutamide—Pleural effusion—Methotrexate—esophageal cancer	0.00283	0.00529	CcSEcCtD
Bicalutamide—Influenza like illness—Capecitabine—esophageal cancer	0.00283	0.00529	CcSEcCtD
Bicalutamide—Urinary incontinence—Capecitabine—esophageal cancer	0.00281	0.00526	CcSEcCtD
Bicalutamide—Hepatotoxicity—Methotrexate—esophageal cancer	0.00281	0.00525	CcSEcCtD
Bicalutamide—Skin ulcer—Methotrexate—esophageal cancer	0.00279	0.00521	CcSEcCtD
Bicalutamide—Face oedema—Cisplatin—esophageal cancer	0.00277	0.00518	CcSEcCtD
Bicalutamide—Neuropathy—Capecitabine—esophageal cancer	0.00274	0.00511	CcSEcCtD
Bicalutamide—Blood creatinine increased—Cisplatin—esophageal cancer	0.00269	0.00502	CcSEcCtD
Bicalutamide—Dehydration—Cisplatin—esophageal cancer	0.00267	0.00499	CcSEcCtD
Bicalutamide—Neoplasm—Capecitabine—esophageal cancer	0.00263	0.00492	CcSEcCtD
Bicalutamide—Ecchymosis—Capecitabine—esophageal cancer	0.00263	0.00492	CcSEcCtD
Bicalutamide—Breast disorder—Cisplatin—esophageal cancer	0.00259	0.00485	CcSEcCtD
Bicalutamide—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00258	0.00483	CcSEcCtD
Bicalutamide—Abnormal vision—Capecitabine—esophageal cancer	0.00254	0.00475	CcSEcCtD
Bicalutamide—Sepsis—Capecitabine—esophageal cancer	0.00253	0.00473	CcSEcCtD
Bicalutamide—Thrombophlebitis—Capecitabine—esophageal cancer	0.00244	0.00457	CcSEcCtD
Bicalutamide—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00243	0.00454	CcSEcCtD
Bicalutamide—Diabetes mellitus—Capecitabine—esophageal cancer	0.00243	0.00454	CcSEcCtD
Bicalutamide—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00242	0.00452	CcSEcCtD
Bicalutamide—Bone disorder—Methotrexate—esophageal cancer	0.0024	0.00449	CcSEcCtD
Bicalutamide—Hepatic failure—Capecitabine—esophageal cancer	0.00235	0.0044	CcSEcCtD
Bicalutamide—Libido decreased—Capecitabine—esophageal cancer	0.00228	0.00426	CcSEcCtD
Bicalutamide—Hot flush—Capecitabine—esophageal cancer	0.00226	0.00423	CcSEcCtD
Bicalutamide—Menopausal symptoms—Capecitabine—esophageal cancer	0.00224	0.00419	CcSEcCtD
Bicalutamide—Atrial fibrillation—Capecitabine—esophageal cancer	0.00223	0.00417	CcSEcCtD
Bicalutamide—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00218	0.00407	CcSEcCtD
Bicalutamide—Arthritis—Capecitabine—esophageal cancer	0.00218	0.00407	CcSEcCtD
Bicalutamide—Myocardial infarction—Cisplatin—esophageal cancer	0.00217	0.00405	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00217	0.00405	CcSEcCtD
Bicalutamide—Cardiac failure—Capecitabine—esophageal cancer	0.00217	0.00405	CcSEcCtD
Bicalutamide—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00216	0.00403	CcSEcCtD
Bicalutamide—Conjunctivitis—Cisplatin—esophageal cancer	0.00215	0.00402	CcSEcCtD
Bicalutamide—Melaena—Methotrexate—esophageal cancer	0.00212	0.00396	CcSEcCtD
Bicalutamide—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.0021	0.00392	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00209	0.00391	CcSEcCtD
Bicalutamide—Face oedema—Capecitabine—esophageal cancer	0.00204	0.00382	CcSEcCtD
Bicalutamide—Bradycardia—Cisplatin—esophageal cancer	0.00202	0.00378	CcSEcCtD
Bicalutamide—Urinary retention—Capecitabine—esophageal cancer	0.00201	0.00376	CcSEcCtD
Bicalutamide—Cardiac arrest—Capecitabine—esophageal cancer	0.00201	0.00376	CcSEcCtD
Bicalutamide—Blood creatinine increased—Capecitabine—esophageal cancer	0.00198	0.0037	CcSEcCtD
Bicalutamide—Dehydration—Capecitabine—esophageal cancer	0.00197	0.00368	CcSEcCtD
Bicalutamide—Ecchymosis—Methotrexate—esophageal cancer	0.00196	0.00366	CcSEcCtD
Bicalutamide—Neoplasm—Methotrexate—esophageal cancer	0.00196	0.00366	CcSEcCtD
Bicalutamide—Urinary tract disorder—Cisplatin—esophageal cancer	0.00196	0.00366	CcSEcCtD
Bicalutamide—Liver function test abnormal—Capecitabine—esophageal cancer	0.00195	0.00365	CcSEcCtD
Bicalutamide—Urethral disorder—Cisplatin—esophageal cancer	0.00195	0.00364	CcSEcCtD
Bicalutamide—Gynaecomastia—Methotrexate—esophageal cancer	0.00194	0.00363	CcSEcCtD
Bicalutamide—Dry skin—Capecitabine—esophageal cancer	0.00194	0.00362	CcSEcCtD
Bicalutamide—Visual impairment—Cisplatin—esophageal cancer	0.00191	0.00357	CcSEcCtD
Bicalutamide—Breast disorder—Capecitabine—esophageal cancer	0.00191	0.00357	CcSEcCtD
Bicalutamide—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.0019	0.00356	CcSEcCtD
Bicalutamide—Sepsis—Methotrexate—esophageal cancer	0.00188	0.00352	CcSEcCtD
Bicalutamide—Gastritis—Capecitabine—esophageal cancer	0.00187	0.0035	CcSEcCtD
Bicalutamide—Muscular weakness—Capecitabine—esophageal cancer	0.00187	0.00349	CcSEcCtD
Bicalutamide—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00187	0.00349	CcSEcCtD
Bicalutamide—Cardiac disorder—Cisplatin—esophageal cancer	0.00184	0.00344	CcSEcCtD
Bicalutamide—Dysphagia—Capecitabine—esophageal cancer	0.00183	0.00342	CcSEcCtD
Bicalutamide—Influenza—Capecitabine—esophageal cancer	0.00183	0.00342	CcSEcCtD
Bicalutamide—Asthma—Capecitabine—esophageal cancer	0.00183	0.00342	CcSEcCtD
Bicalutamide—Thrombophlebitis—Methotrexate—esophageal cancer	0.00182	0.0034	CcSEcCtD
Bicalutamide—Diabetes mellitus—Methotrexate—esophageal cancer	0.00181	0.00338	CcSEcCtD
Bicalutamide—Immune system disorder—Cisplatin—esophageal cancer	0.00179	0.00335	CcSEcCtD
Bicalutamide—Mediastinal disorder—Cisplatin—esophageal cancer	0.00179	0.00334	CcSEcCtD
Bicalutamide—Angina pectoris—Capecitabine—esophageal cancer	0.00178	0.00333	CcSEcCtD
Bicalutamide—Arrhythmia—Cisplatin—esophageal cancer	0.00177	0.00331	CcSEcCtD
Bicalutamide—Bronchitis—Capecitabine—esophageal cancer	0.00176	0.00329	CcSEcCtD
Bicalutamide—Alopecia—Cisplatin—esophageal cancer	0.00175	0.00328	CcSEcCtD
Bicalutamide—Hepatic failure—Methotrexate—esophageal cancer	0.00175	0.00327	CcSEcCtD
Bicalutamide—Malnutrition—Cisplatin—esophageal cancer	0.00173	0.00323	CcSEcCtD
Bicalutamide—Dysuria—Capecitabine—esophageal cancer	0.00171	0.00319	CcSEcCtD
Bicalutamide—Neutropenia—Capecitabine—esophageal cancer	0.00171	0.00319	CcSEcCtD
Bicalutamide—Flatulence—Cisplatin—esophageal cancer	0.0017	0.00318	CcSEcCtD
Bicalutamide—Weight increased—Capecitabine—esophageal cancer	0.00166	0.00311	CcSEcCtD
Bicalutamide—Muscle spasms—Cisplatin—esophageal cancer	0.00166	0.0031	CcSEcCtD
Bicalutamide—Weight decreased—Capecitabine—esophageal cancer	0.00165	0.00309	CcSEcCtD
Bicalutamide—Hyperglycaemia—Capecitabine—esophageal cancer	0.00165	0.00308	CcSEcCtD
Bicalutamide—Pneumonia—Capecitabine—esophageal cancer	0.00164	0.00306	CcSEcCtD
Bicalutamide—Depression—Capecitabine—esophageal cancer	0.00163	0.00304	CcSEcCtD
Bicalutamide—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00161	0.003	CcSEcCtD
Bicalutamide—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00161	0.003	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Capecitabine—esophageal cancer	0.0016	0.00299	CcSEcCtD
Bicalutamide—Myocardial infarction—Capecitabine—esophageal cancer	0.0016	0.00299	CcSEcCtD
Bicalutamide—Anaemia—Cisplatin—esophageal cancer	0.0016	0.00298	CcSEcCtD
Bicalutamide—Jaundice—Capecitabine—esophageal cancer	0.00159	0.00297	CcSEcCtD
Bicalutamide—Conjunctivitis—Capecitabine—esophageal cancer	0.00158	0.00296	CcSEcCtD
Bicalutamide—Urinary tract infection—Capecitabine—esophageal cancer	0.00158	0.00296	CcSEcCtD
Bicalutamide—Haematuria—Capecitabine—esophageal cancer	0.00155	0.0029	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00154	0.00288	CcSEcCtD
Bicalutamide—Epistaxis—Capecitabine—esophageal cancer	0.00154	0.00287	CcSEcCtD
Bicalutamide—Bradycardia—Capecitabine—esophageal cancer	0.00149	0.00278	CcSEcCtD
Bicalutamide—Myalgia—Cisplatin—esophageal cancer	0.00147	0.00275	CcSEcCtD
Bicalutamide—Haemoglobin—Capecitabine—esophageal cancer	0.00147	0.00275	CcSEcCtD
Bicalutamide—Rhinitis—Capecitabine—esophageal cancer	0.00147	0.00274	CcSEcCtD
Bicalutamide—Anxiety—Cisplatin—esophageal cancer	0.00147	0.00274	CcSEcCtD
Bicalutamide—Haemorrhage—Capecitabine—esophageal cancer	0.00146	0.00273	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00146	0.00273	CcSEcCtD
Bicalutamide—Liver function test abnormal—Methotrexate—esophageal cancer	0.00145	0.00272	CcSEcCtD
Bicalutamide—Pharyngitis—Capecitabine—esophageal cancer	0.00145	0.00271	CcSEcCtD
Bicalutamide—Urinary tract disorder—Capecitabine—esophageal cancer	0.00145	0.0027	CcSEcCtD
Bicalutamide—Oedema peripheral—Capecitabine—esophageal cancer	0.00144	0.00269	CcSEcCtD
Bicalutamide—Urethral disorder—Capecitabine—esophageal cancer	0.00143	0.00268	CcSEcCtD
Bicalutamide—Breast disorder—Methotrexate—esophageal cancer	0.00142	0.00266	CcSEcCtD
Bicalutamide—Oedema—Cisplatin—esophageal cancer	0.00141	0.00264	CcSEcCtD
Bicalutamide—Visual impairment—Capecitabine—esophageal cancer	0.00141	0.00264	CcSEcCtD
Bicalutamide—Infection—Cisplatin—esophageal cancer	0.0014	0.00262	CcSEcCtD
Bicalutamide—Nervous system disorder—Cisplatin—esophageal cancer	0.00138	0.00258	CcSEcCtD
Bicalutamide—Thrombocytopenia—Cisplatin—esophageal cancer	0.00138	0.00258	CcSEcCtD
Bicalutamide—Skin disorder—Cisplatin—esophageal cancer	0.00137	0.00256	CcSEcCtD
Bicalutamide—Hyperhidrosis—Cisplatin—esophageal cancer	0.00136	0.00255	CcSEcCtD
Bicalutamide—Asthma—Methotrexate—esophageal cancer	0.00136	0.00254	CcSEcCtD
Bicalutamide—Cardiac disorder—Capecitabine—esophageal cancer	0.00136	0.00254	CcSEcCtD
Bicalutamide—Eosinophilia—Methotrexate—esophageal cancer	0.00135	0.00252	CcSEcCtD
Bicalutamide—Anorexia—Cisplatin—esophageal cancer	0.00134	0.00251	CcSEcCtD
Bicalutamide—Angiopathy—Capecitabine—esophageal cancer	0.00133	0.00248	CcSEcCtD
Bicalutamide—Immune system disorder—Capecitabine—esophageal cancer	0.00132	0.00247	CcSEcCtD
Bicalutamide—Mediastinal disorder—Capecitabine—esophageal cancer	0.00132	0.00246	CcSEcCtD
Bicalutamide—Chills—Capecitabine—esophageal cancer	0.00131	0.00245	CcSEcCtD
Bicalutamide—Arrhythmia—Capecitabine—esophageal cancer	0.00131	0.00244	CcSEcCtD
Bicalutamide—Alopecia—Capecitabine—esophageal cancer	0.00129	0.00242	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00128	0.0024	CcSEcCtD
Bicalutamide—Mental disorder—Capecitabine—esophageal cancer	0.00128	0.0024	CcSEcCtD
Bicalutamide—Malnutrition—Capecitabine—esophageal cancer	0.00127	0.00238	CcSEcCtD
Bicalutamide—Neutropenia—Methotrexate—esophageal cancer	0.00127	0.00238	CcSEcCtD
Bicalutamide—Dysuria—Methotrexate—esophageal cancer	0.00127	0.00238	CcSEcCtD
Bicalutamide—Paraesthesia—Cisplatin—esophageal cancer	0.00127	0.00237	CcSEcCtD
Bicalutamide—Dyspnoea—Cisplatin—esophageal cancer	0.00126	0.00235	CcSEcCtD
Bicalutamide—Flatulence—Capecitabine—esophageal cancer	0.00126	0.00235	CcSEcCtD
Bicalutamide—Erectile dysfunction—Methotrexate—esophageal cancer	0.00125	0.00234	CcSEcCtD
Bicalutamide—Back pain—Capecitabine—esophageal cancer	0.00123	0.0023	CcSEcCtD
Bicalutamide—Decreased appetite—Cisplatin—esophageal cancer	0.00123	0.00229	CcSEcCtD
Bicalutamide—Muscle spasms—Capecitabine—esophageal cancer	0.00122	0.00229	CcSEcCtD
Bicalutamide—Pneumonia—Methotrexate—esophageal cancer	0.00122	0.00228	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00122	0.00228	CcSEcCtD
Bicalutamide—Depression—Methotrexate—esophageal cancer	0.00121	0.00226	CcSEcCtD
Bicalutamide—Pain—Cisplatin—esophageal cancer	0.00121	0.00225	CcSEcCtD
Bicalutamide—Conjunctivitis—Methotrexate—esophageal cancer	0.00118	0.0022	CcSEcCtD
Bicalutamide—Anaemia—Capecitabine—esophageal cancer	0.00118	0.0022	CcSEcCtD
Bicalutamide—Sweating—Methotrexate—esophageal cancer	0.00116	0.00217	CcSEcCtD
Bicalutamide—Feeling abnormal—Cisplatin—esophageal cancer	0.00116	0.00217	CcSEcCtD
Bicalutamide—Haematuria—Methotrexate—esophageal cancer	0.00116	0.00216	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00115	0.00214	CcSEcCtD
Bicalutamide—Epistaxis—Methotrexate—esophageal cancer	0.00114	0.00214	CcSEcCtD
Bicalutamide—Syncope—Capecitabine—esophageal cancer	0.00114	0.00213	CcSEcCtD
Bicalutamide—Loss of consciousness—Capecitabine—esophageal cancer	0.00112	0.00209	CcSEcCtD
Bicalutamide—Body temperature increased—Cisplatin—esophageal cancer	0.00111	0.00208	CcSEcCtD
Bicalutamide—Cough—Capecitabine—esophageal cancer	0.00111	0.00208	CcSEcCtD
Bicalutamide—Hypertension—Capecitabine—esophageal cancer	0.0011	0.00206	CcSEcCtD
Bicalutamide—Haemoglobin—Methotrexate—esophageal cancer	0.00109	0.00205	CcSEcCtD
Bicalutamide—Haemorrhage—Methotrexate—esophageal cancer	0.00109	0.00204	CcSEcCtD
Bicalutamide—Chest pain—Capecitabine—esophageal cancer	0.00108	0.00203	CcSEcCtD
Bicalutamide—Myalgia—Capecitabine—esophageal cancer	0.00108	0.00203	CcSEcCtD
Bicalutamide—Pharyngitis—Methotrexate—esophageal cancer	0.00108	0.00202	CcSEcCtD
Bicalutamide—Anxiety—Capecitabine—esophageal cancer	0.00108	0.00202	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00108	0.00201	CcSEcCtD
Bicalutamide—Urinary tract disorder—Methotrexate—esophageal cancer	0.00108	0.00201	CcSEcCtD
Bicalutamide—Urethral disorder—Methotrexate—esophageal cancer	0.00107	0.002	CcSEcCtD
Bicalutamide—Dry mouth—Capecitabine—esophageal cancer	0.00106	0.00198	CcSEcCtD
Bicalutamide—Visual impairment—Methotrexate—esophageal cancer	0.00105	0.00196	CcSEcCtD
Bicalutamide—Confusional state—Capecitabine—esophageal cancer	0.00105	0.00196	CcSEcCtD
Bicalutamide—Oedema—Capecitabine—esophageal cancer	0.00104	0.00194	CcSEcCtD
Bicalutamide—Hypersensitivity—Cisplatin—esophageal cancer	0.00104	0.00194	CcSEcCtD
Bicalutamide—Infection—Capecitabine—esophageal cancer	0.00103	0.00193	CcSEcCtD
Bicalutamide—Shock—Capecitabine—esophageal cancer	0.00102	0.00191	CcSEcCtD
Bicalutamide—Nervous system disorder—Capecitabine—esophageal cancer	0.00102	0.00191	CcSEcCtD
Bicalutamide—Thrombocytopenia—Capecitabine—esophageal cancer	0.00102	0.0019	CcSEcCtD
Bicalutamide—Asthenia—Cisplatin—esophageal cancer	0.00101	0.00189	CcSEcCtD
Bicalutamide—Cardiac disorder—Methotrexate—esophageal cancer	0.00101	0.00189	CcSEcCtD
Bicalutamide—Skin disorder—Capecitabine—esophageal cancer	0.00101	0.00189	CcSEcCtD
Bicalutamide—Hyperhidrosis—Capecitabine—esophageal cancer	0.00101	0.00188	CcSEcCtD
Bicalutamide—Anorexia—Capecitabine—esophageal cancer	0.000991	0.00185	CcSEcCtD
Bicalutamide—Angiopathy—Methotrexate—esophageal cancer	0.000988	0.00185	CcSEcCtD
Bicalutamide—Immune system disorder—Methotrexate—esophageal cancer	0.000984	0.00184	CcSEcCtD
Bicalutamide—Mediastinal disorder—Methotrexate—esophageal cancer	0.000982	0.00183	CcSEcCtD
Bicalutamide—Chills—Methotrexate—esophageal cancer	0.000977	0.00183	CcSEcCtD
Bicalutamide—Diarrhoea—Cisplatin—esophageal cancer	0.000965	0.0018	CcSEcCtD
Bicalutamide—Alopecia—Methotrexate—esophageal cancer	0.000963	0.0018	CcSEcCtD
Bicalutamide—Mental disorder—Methotrexate—esophageal cancer	0.000954	0.00178	CcSEcCtD
Bicalutamide—Malnutrition—Methotrexate—esophageal cancer	0.000948	0.00177	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000947	0.00177	CcSEcCtD
Bicalutamide—Insomnia—Capecitabine—esophageal cancer	0.00094	0.00176	CcSEcCtD
Bicalutamide—Paraesthesia—Capecitabine—esophageal cancer	0.000934	0.00174	CcSEcCtD
Bicalutamide—Dyspnoea—Capecitabine—esophageal cancer	0.000927	0.00173	CcSEcCtD
Bicalutamide—Back pain—Methotrexate—esophageal cancer	0.000917	0.00171	CcSEcCtD
Bicalutamide—Dyspepsia—Capecitabine—esophageal cancer	0.000915	0.00171	CcSEcCtD
Bicalutamide—Decreased appetite—Capecitabine—esophageal cancer	0.000904	0.00169	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000898	0.00168	CcSEcCtD
Bicalutamide—Vomiting—Cisplatin—esophageal cancer	0.000897	0.00168	CcSEcCtD
Bicalutamide—Fatigue—Capecitabine—esophageal cancer	0.000896	0.00167	CcSEcCtD
Bicalutamide—Rash—Cisplatin—esophageal cancer	0.000889	0.00166	CcSEcCtD
Bicalutamide—Pain—Capecitabine—esophageal cancer	0.000889	0.00166	CcSEcCtD
Bicalutamide—Constipation—Capecitabine—esophageal cancer	0.000889	0.00166	CcSEcCtD
Bicalutamide—Dermatitis—Cisplatin—esophageal cancer	0.000888	0.00166	CcSEcCtD
Bicalutamide—Anaemia—Methotrexate—esophageal cancer	0.000876	0.00164	CcSEcCtD
Bicalutamide—Feeling abnormal—Capecitabine—esophageal cancer	0.000857	0.0016	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00085	0.00159	CcSEcCtD
Bicalutamide—Nausea—Cisplatin—esophageal cancer	0.000838	0.00157	CcSEcCtD
Bicalutamide—Cough—Methotrexate—esophageal cancer	0.000828	0.00155	CcSEcCtD
Bicalutamide—Urticaria—Capecitabine—esophageal cancer	0.000826	0.00154	CcSEcCtD
Bicalutamide—Abdominal pain—Capecitabine—esophageal cancer	0.000822	0.00154	CcSEcCtD
Bicalutamide—Body temperature increased—Capecitabine—esophageal cancer	0.000822	0.00154	CcSEcCtD
Bicalutamide—Chest pain—Methotrexate—esophageal cancer	0.000807	0.00151	CcSEcCtD
Bicalutamide—Myalgia—Methotrexate—esophageal cancer	0.000807	0.00151	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000802	0.0015	CcSEcCtD
Bicalutamide—Confusional state—Methotrexate—esophageal cancer	0.00078	0.00146	CcSEcCtD
Bicalutamide—Infection—Methotrexate—esophageal cancer	0.000769	0.00144	CcSEcCtD
Bicalutamide—Hypersensitivity—Capecitabine—esophageal cancer	0.000766	0.00143	CcSEcCtD
Bicalutamide—Nervous system disorder—Methotrexate—esophageal cancer	0.000759	0.00142	CcSEcCtD
Bicalutamide—Thrombocytopenia—Methotrexate—esophageal cancer	0.000758	0.00142	CcSEcCtD
Bicalutamide—Skin disorder—Methotrexate—esophageal cancer	0.000752	0.0014	CcSEcCtD
Bicalutamide—Hyperhidrosis—Methotrexate—esophageal cancer	0.000748	0.0014	CcSEcCtD
Bicalutamide—Asthenia—Capecitabine—esophageal cancer	0.000746	0.00139	CcSEcCtD
Bicalutamide—Anorexia—Methotrexate—esophageal cancer	0.000738	0.00138	CcSEcCtD
Bicalutamide—Pruritus—Capecitabine—esophageal cancer	0.000736	0.00137	CcSEcCtD
Bicalutamide—Diarrhoea—Capecitabine—esophageal cancer	0.000711	0.00133	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000705	0.00132	CcSEcCtD
Bicalutamide—Insomnia—Methotrexate—esophageal cancer	0.0007	0.00131	CcSEcCtD
Bicalutamide—Paraesthesia—Methotrexate—esophageal cancer	0.000695	0.0013	CcSEcCtD
Bicalutamide—Dyspnoea—Methotrexate—esophageal cancer	0.00069	0.00129	CcSEcCtD
Bicalutamide—Somnolence—Methotrexate—esophageal cancer	0.000688	0.00129	CcSEcCtD
Bicalutamide—Dizziness—Capecitabine—esophageal cancer	0.000688	0.00128	CcSEcCtD
Bicalutamide—Dyspepsia—Methotrexate—esophageal cancer	0.000681	0.00127	CcSEcCtD
Bicalutamide—Decreased appetite—Methotrexate—esophageal cancer	0.000673	0.00126	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000668	0.00125	CcSEcCtD
Bicalutamide—Fatigue—Methotrexate—esophageal cancer	0.000667	0.00125	CcSEcCtD
Bicalutamide—Pain—Methotrexate—esophageal cancer	0.000662	0.00124	CcSEcCtD
Bicalutamide—Vomiting—Capecitabine—esophageal cancer	0.000661	0.00124	CcSEcCtD
Bicalutamide—Rash—Capecitabine—esophageal cancer	0.000656	0.00122	CcSEcCtD
Bicalutamide—Dermatitis—Capecitabine—esophageal cancer	0.000655	0.00122	CcSEcCtD
Bicalutamide—Headache—Capecitabine—esophageal cancer	0.000651	0.00122	CcSEcCtD
Bicalutamide—Feeling abnormal—Methotrexate—esophageal cancer	0.000638	0.00119	CcSEcCtD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000637	0.00165	CbGpPWpGaD
Bicalutamide—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000633	0.00118	CcSEcCtD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000632	0.00164	CbGpPWpGaD
Bicalutamide—Nausea—Capecitabine—esophageal cancer	0.000618	0.00115	CcSEcCtD
Bicalutamide—Urticaria—Methotrexate—esophageal cancer	0.000615	0.00115	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—EP300—esophageal cancer	0.000613	0.00159	CbGpPWpGaD
Bicalutamide—Body temperature increased—Methotrexate—esophageal cancer	0.000612	0.00114	CcSEcCtD
Bicalutamide—Abdominal pain—Methotrexate—esophageal cancer	0.000612	0.00114	CcSEcCtD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000603	0.00156	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.000601	0.00156	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.000595	0.00155	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CASP8—esophageal cancer	0.000593	0.00154	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.000592	0.00154	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—RB1—esophageal cancer	0.000588	0.00153	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000587	0.00152	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—esophageal cancer	0.000582	0.00151	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—esophageal cancer	0.000576	0.0015	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000575	0.00149	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Methotrexate—esophageal cancer	0.00057	0.00107	CcSEcCtD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000567	0.00147	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000563	0.00146	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000556	0.00144	CbGpPWpGaD
Bicalutamide—Asthenia—Methotrexate—esophageal cancer	0.000555	0.00104	CcSEcCtD
Bicalutamide—Pruritus—Methotrexate—esophageal cancer	0.000548	0.00102	CcSEcCtD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000537	0.00139	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—ALDH2—esophageal cancer	0.000532	0.00138	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00053	0.00137	CbGpPWpGaD
Bicalutamide—Diarrhoea—Methotrexate—esophageal cancer	0.00053	0.000989	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—EGFR—esophageal cancer	0.000523	0.00136	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000523	0.00136	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000518	0.00134	CbGpPWpGaD
Bicalutamide—Dizziness—Methotrexate—esophageal cancer	0.000512	0.000956	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BCL2—esophageal cancer	0.000509	0.00132	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—GSTT1—esophageal cancer	0.000506	0.00131	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP2A6—esophageal cancer	0.000501	0.0013	CbGpPWpGaD
Bicalutamide—Vomiting—Methotrexate—esophageal cancer	0.000492	0.000919	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.000491	0.00127	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.00049	0.00127	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.000489	0.00127	CbGpPWpGaD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000489	0.00127	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—SMG6—esophageal cancer	0.000488	0.00127	CbGpPWpGaD
Bicalutamide—Rash—Methotrexate—esophageal cancer	0.000488	0.000912	CcSEcCtD
Bicalutamide—Dermatitis—Methotrexate—esophageal cancer	0.000488	0.000911	CcSEcCtD
Bicalutamide—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000485	0.00126	CbGpPWpGaD
Bicalutamide—Headache—Methotrexate—esophageal cancer	0.000485	0.000906	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.000483	0.00125	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—PTGS1—esophageal cancer	0.000474	0.00123	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.000466	0.00121	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000462	0.0012	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.00046	0.00119	CbGpPWpGaD
Bicalutamide—Nausea—Methotrexate—esophageal cancer	0.00046	0.000859	CcSEcCtD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000457	0.00119	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.000456	0.00118	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000454	0.00118	CbGpPWpGaD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000445	0.00116	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CCND1—esophageal cancer	0.000437	0.00113	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.000436	0.00113	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.000433	0.00112	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000433	0.00112	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000429	0.00111	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000422	0.0011	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	0.000422	0.00109	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000417	0.00108	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.00041	0.00106	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP1B1—esophageal cancer	0.000403	0.00105	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—EP300—esophageal cancer	0.000402	0.00104	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.0004	0.00104	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000398	0.00103	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000393	0.00102	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000392	0.00102	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000389	0.00101	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000387	0.00101	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP19A1—esophageal cancer	0.000379	0.000985	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000374	0.000971	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000371	0.000963	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—NR1I2—esophageal cancer	0.00037	0.00096	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000368	0.000955	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000366	0.00095	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—SMAD4—esophageal cancer	0.000363	0.000943	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000363	0.000942	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	0.000362	0.000939	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000355	0.000921	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MYC—esophageal cancer	0.00035	0.000909	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	0.00035	0.000908	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000349	0.000906	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000346	0.000898	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000344	0.000893	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—EGFR—esophageal cancer	0.000343	0.000889	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000341	0.000885	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	0.000333	0.000864	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.00032	0.000831	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—HIST1H2BM—esophageal cancer	0.000317	0.000824	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000304	0.00079	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000301	0.000781	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	0.00029	0.000753	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—TP53—esophageal cancer	0.000288	0.000746	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000285	0.000741	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	0.000284	0.000737	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000268	0.000695	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000263	0.000682	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	0.000246	0.000639	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PSME2—esophageal cancer	0.000246	0.000639	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PSME1—esophageal cancer	0.000246	0.000639	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—CREBBP—esophageal cancer	0.000243	0.00063	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000243	0.00063	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.00024	0.000622	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000239	0.000621	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.000238	0.000619	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—NOTCH3—esophageal cancer	0.000232	0.000603	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000229	0.000595	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000228	0.000592	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000225	0.000584	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000209	0.000543	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—NOTCH2—esophageal cancer	0.000208	0.000541	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—BLVRB—esophageal cancer	0.000204	0.000529	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SLC52A3—esophageal cancer	0.000204	0.000529	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000187	0.000487	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000187	0.000487	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000186	0.000482	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000186	0.000482	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000182	0.000473	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—SMAD4—esophageal cancer	0.000175	0.000454	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CA1—esophageal cancer	0.000173	0.00045	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SLC10A2—esophageal cancer	0.000173	0.00045	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000166	0.000431	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CA1—esophageal cancer	0.000159	0.000414	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000159	0.000414	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CA2—esophageal cancer	0.000159	0.000411	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.000158	0.00041	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CA1—esophageal cancer	0.000158	0.00041	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000155	0.000402	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PLCE1—esophageal cancer	0.000147	0.000382	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ADH7—esophageal cancer	0.000147	0.000382	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CA2—esophageal cancer	0.000146	0.000378	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000146	0.000378	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CA2—esophageal cancer	0.000145	0.000375	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—MYC—esophageal cancer	0.000144	0.000374	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000141	0.000367	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000136	0.000352	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000136	0.000352	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.000134	0.000349	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ADH7—esophageal cancer	0.000134	0.000349	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000133	0.000345	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ADH1B—esophageal cancer	0.000129	0.000335	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—NOTCH1—esophageal cancer	0.000129	0.000335	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—TYMP—esophageal cancer	0.000123	0.000321	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000123	0.000318	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000123	0.000318	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP26A1—esophageal cancer	0.00012	0.000312	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000119	0.000308	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ADH1B—esophageal cancer	0.000118	0.000306	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ALOX15—esophageal cancer	0.000117	0.000304	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—CREBBP—esophageal cancer	0.000117	0.000304	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000114	0.000295	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—TYMP—esophageal cancer	0.000113	0.000292	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—TPI1—esophageal cancer	0.000112	0.00029	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTO1—esophageal cancer	0.000112	0.00029	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.00011	0.000287	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP26A1—esophageal cancer	0.00011	0.000284	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000108	0.000279	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ALDOB—esophageal cancer	0.000107	0.000278	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ALOX15—esophageal cancer	0.000107	0.000277	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000104	0.00027	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CA1—esophageal cancer	0.000104	0.00027	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GAPDH—esophageal cancer	0.000103	0.000267	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000103	0.000267	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000103	0.000267	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CRABP1—esophageal cancer	0.000102	0.000265	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTO1—esophageal cancer	0.000102	0.000264	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—TPI1—esophageal cancer	0.000102	0.000264	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ALDOB—esophageal cancer	9.85e-05	0.000256	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ALDOB—esophageal cancer	9.76e-05	0.000253	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GNG7—esophageal cancer	9.72e-05	0.000252	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CA2—esophageal cancer	9.53e-05	0.000247	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GAPDH—esophageal cancer	9.48e-05	0.000246	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GAPDH—esophageal cancer	9.4e-05	0.000244	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CRABP1—esophageal cancer	9.39e-05	0.000244	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CRABP1—esophageal cancer	9.31e-05	0.000242	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ALDH2—esophageal cancer	9.1e-05	0.000236	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GNG7—esophageal cancer	8.94e-05	0.000232	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PLCE1—esophageal cancer	8.86e-05	0.00023	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ADH7—esophageal cancer	8.86e-05	0.00023	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GNG7—esophageal cancer	8.86e-05	0.00023	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTT1—esophageal cancer	8.66e-05	0.000225	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP2A6—esophageal cancer	8.56e-05	0.000222	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.53e-05	0.000221	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ALDH2—esophageal cancer	8.37e-05	0.000217	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ALDH2—esophageal cancer	8.3e-05	0.000215	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ENO1—esophageal cancer	8.11e-05	0.000211	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTGS1—esophageal cancer	8.11e-05	0.000211	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PSME2—esophageal cancer	8e-05	0.000208	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PSME1—esophageal cancer	8e-05	0.000208	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTT1—esophageal cancer	7.96e-05	0.000207	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTT1—esophageal cancer	7.9e-05	0.000205	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP2A6—esophageal cancer	7.87e-05	0.000204	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP2A6—esophageal cancer	7.8e-05	0.000203	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	7.77e-05	0.000202	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ADH1B—esophageal cancer	7.77e-05	0.000202	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTGS1—esophageal cancer	7.46e-05	0.000194	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ENO1—esophageal cancer	7.46e-05	0.000194	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TYMP—esophageal cancer	7.43e-05	0.000193	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ENO1—esophageal cancer	7.4e-05	0.000192	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTGS1—esophageal cancer	7.4e-05	0.000192	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PSME2—esophageal cancer	7.35e-05	0.000191	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PSME1—esophageal cancer	7.35e-05	0.000191	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PSME1—esophageal cancer	7.29e-05	0.000189	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PSME2—esophageal cancer	7.29e-05	0.000189	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP26A1—esophageal cancer	7.22e-05	0.000187	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ALOX15—esophageal cancer	7.04e-05	0.000183	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.98e-05	0.000181	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—MYC—esophageal cancer	6.94e-05	0.00018	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP1B1—esophageal cancer	6.9e-05	0.000179	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTO1—esophageal cancer	6.72e-05	0.000174	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TPI1—esophageal cancer	6.72e-05	0.000174	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP19A1—esophageal cancer	6.49e-05	0.000168	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ALDOB—esophageal cancer	6.44e-05	0.000167	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.37e-05	0.000165	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP1B1—esophageal cancer	6.35e-05	0.000165	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP1B1—esophageal cancer	6.29e-05	0.000163	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GAPDH—esophageal cancer	6.2e-05	0.000161	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CRABP1—esophageal cancer	6.14e-05	0.000159	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP19A1—esophageal cancer	5.97e-05	0.000155	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—HMOX1—esophageal cancer	5.92e-05	0.000154	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP19A1—esophageal cancer	5.91e-05	0.000154	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GNG7—esophageal cancer	5.84e-05	0.000152	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.81e-05	0.000151	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ABCB1—esophageal cancer	5.68e-05	0.000147	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ALDH2—esophageal cancer	5.47e-05	0.000142	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—HMOX1—esophageal cancer	5.44e-05	0.000141	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—HMOX1—esophageal cancer	5.4e-05	0.00014	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.3e-05	0.000137	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ABCB1—esophageal cancer	5.23e-05	0.000136	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTT1—esophageal cancer	5.21e-05	0.000135	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ABCB1—esophageal cancer	5.18e-05	0.000134	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP2A6—esophageal cancer	5.15e-05	0.000134	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ENO1—esophageal cancer	4.88e-05	0.000127	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.88e-05	0.000127	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PSME1—esophageal cancer	4.81e-05	0.000125	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PSME2—esophageal cancer	4.81e-05	0.000125	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.3e-05	0.000111	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.15e-05	0.000108	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.92e-05	0.000102	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.9e-05	0.000101	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CREBBP—esophageal cancer	3.8e-05	9.86e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.56e-05	9.24e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.49e-05	9.06e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CREBBP—esophageal cancer	3.46e-05	8.99e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.42e-05	8.87e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NOS3—esophageal cancer	3.4e-05	8.82e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NOS3—esophageal cancer	3.13e-05	8.12e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTGS2—esophageal cancer	3.11e-05	8.07e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NOS3—esophageal cancer	3.1e-05	8.05e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.86e-05	7.42e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTGS2—esophageal cancer	2.84e-05	7.36e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—EP300—esophageal cancer	2.59e-05	6.71e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—EP300—esophageal cancer	2.38e-05	6.17e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—EP300—esophageal cancer	2.36e-05	6.12e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.28e-05	5.93e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NOS3—esophageal cancer	2.04e-05	5.31e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CA—esophageal cancer	1.91e-05	4.97e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.87e-05	4.85e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.76e-05	4.57e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.74e-05	4.53e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—EP300—esophageal cancer	1.56e-05	4.04e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.15e-05	2.99e-05	CbGpPWpGaD
